Related Experiment Video
Updated: Aug 10, 2026

Isolation and Physiological Analysis of Mouse Cardiomyocytes
Published on: September 7, 2014
Cellular and molecular aspects of myocardial dysfunction
S M Schwartz1, J Y Duffy, J M Pearl
1Division of Cardiology, Children's Hospital Medical Center, Cincinnati, OH 45229-3039, USA. schws0@chmcc.org
Insights
Myocardial dysfunction arises from disruptions in cardiomyocyte systems, triggered by acute or chronic stresses. Understanding these disruptions allows for targeted therapies, especially in pediatric patients.
Area of Science:
- Cardiology
- Cellular Biology
- Pharmacology
Background:
- Myocardial dysfunction stems from disruptions in complex cellular systems maintaining cardiomyocyte structure and function.
- Both acute stresses (e.g., cardiac surgery) and chronic factors (e.g., genetic abnormalities, ischemia) can precipitate myocardial dysfunction.
- Existing therapies impact cardiomyocytes broadly, with effects often exceeding initial clinical appreciation.
Purpose of the Study:
- To explore the multifaceted causes of myocardial dysfunction.
- To examine the broad cellular effects of current cardiovascular therapies.
- To highlight the need for precise, individualized therapeutic strategies in pediatric cardiology.
Main Methods:
- Review of existing literature on cardiomyocyte function and myocardial dysfunction.
- Analysis of the mechanisms of action for various cardiovascular therapies.
- Discussion of the implications of cellular and genetic variability in treatment.
Main Results:
- Disruption of cardiomyocyte systems is a common pathway to myocardial dysfunction.
- Current therapies, including beta-blockers and ACE inhibitors, exert widespread effects on cardiomyocytes.
- Individual genetic variability and specific cellular perturbations are key factors in treatment response.
Conclusions:
- Increased understanding of myocardial dysfunction facilitates targeted interventions.
- Personalized medicine approaches are crucial for optimizing treatment in neonatal and pediatric patients.
- Future therapies will likely focus on highly specific cellular targets and genetic profiles.
Abstract:
Disruption of any one of a large number of balanced systems that maintain cardiomyocyte structure and function can cause myocardial dysfunction. Such disruption can occur either in response to acute stresses such as cardiac surgery with cardiopulmonary bypass and cross-clamping of the aorta or because of more chronic stresses resulting from factors such as genetic abnormalities, infection, or chronic ischemia. Several currently available therapies such as beta-adrenergic receptor agonists and antagonists, phosphodiesterase inhibitors, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and other agents affect cardiomyocytes in ways that are more far reaching than initially appreciated when these agents were first introduced into clinical practice. As our knowledge and understanding of myocardial dysfunction increases, particularly in the neonatal and pediatric patient, we will be able to further target interventions to highly specific perturbations of cellular function and individual genetic variability.
Related Concept Videos
Pathophysiology of Cardiac Performance
Pathophysiology of Heart Failure
Myocarditis I: Introduction
Heart Failure II: Pathophysiology
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy

